Shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) have received an average rating of “Hold” from the six analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has issued a buy recommendation on the company.
A number of research analysts have recently commented on HKMPF shares. Jefferies Group downgraded Hikma Pharmaceuticals from a “hold” rating to an “underperform” rating in a research report on Wednesday, January 10th. ValuEngine upgraded Hikma Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. Finally, Zacks Investment Research upgraded Hikma Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th.
HKMPF remained flat at $$17.10 during trading on Tuesday. Hikma Pharmaceuticals has a 52 week low of $12.00 and a 52 week high of $25.35.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.